Following the publication of this article, the authors have noticed errors in Fig. 1a, b that were caused due to combined and accidental placement of unrelated data obtained from database search. The authors have corrected these figures. The amended version of Fig. 1 is shown below. Accordingly, the fifth sentence in the first subsection of the Results section is corrected as “Survival analysis of lung cancer data in cBioPortal using an online Kaplan–Meier analysis software revealed that patients with lung cancer exhibiting the top 9.2% high USP17 expression have a significantly lower survival rate than that of patients with a lower USP17 expression (Fig. 1b).” This correction does not affect the conclusions depicted in Fig. 1a regarding high USP17 expression in lung cancers and those depicted in Fig. 1b for the correlation between high USP17 expression and lower survival rate of patients with lung cancer. These conclusions are also supported by other published data [1–3] and our experimental data shown in Fig. 1c, wherein the analysis of USP17 expression in the cDNA array of lung cancers by RT-qPCR demonstrated high expression of USP17 in lung cancers, in particular lung cancers at high stages. The high expression and the pro-tumoral effect of USP17 (DUB3/USP17L2) have also been reported for other tumor types [4–7]. The authors express their sincere apologies for these errors and any inconvenience caused.
